Skip to main content

Table 1 COI-studies in HF: Summary of main study characteristics

From: Cost-of-illness studies in heart failure: a systematic review 2004–2016

Reference Country Study size Epidemiological approach Method of Resource Quantification Study period Perspective Study design Mean age
Voigt 2014 [35] USA Prevalenta Mixeda 2007–2012 Sa R
Corrao 2014 [33] Italy 26,949 Incident Top-downa 2011 P R 79
Czech 2013 [36] Poland Prevalenta Mixeda 2009–2011 P R
Delgado 2013 [37] Spain 374 Prevalenta Bottom-upa 2010 S Pr 62
Dunlay 2011 [34] USA 1054 Incidenta Top-downa 1987–2006 Pa R 76,8
Bogner 2010 [24] USA 7996 Prevalenta Bottom-upa 2000–2001 P R 77,8–81,4
Zugck 2010 [30] Germany 86,493 Prevalenta Top-downa 2002 Pa R
Neumann 2009 [29] Germany Prevalenta Top-downa 2000–2007 Pa R
Liao 2007 [23] USA 4860 Prevalent Top-down 1992–2003 Pa Pr 75,6- 78,2
Liao 2006 [25] USA 881 Mixed Top-down 1992–1998 Pa Pr 77,6- 81,6
Agvall 2005 [28] Sweden 115 Prevalenta Bottom-upa 1999–2000 Pa R 77
Ory 2005 [26] USA 17,835 Mixed Bottom-upa 1999–2001 Pa Pr 76,4
Stafylas 2016 [38] Greece 307 Prevalent Top-downa 2009–2011 P Pr 66
Lee 2016 [31] South Korea 475,019 Prevalent Top-down 2014 P / S R
Murphy 2016 [27] Ireland 1292 Mixeda Mixeda 2013 Pa R 74,5
Ogah 2014 [32] Nigeria 239 Prevalent Mixeda 2009–2010 S Pr 58
  1. anot clearly stated in the study, consensus by discussion
  2. S – societal; P – third-party payer; R – retrospective; Pr - prospective